MedTrace Logo

Impact of Filtration on Autologous Serum Eye Drops

NCT07407101 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-29

No results posted yet for this study

Summary

Dry eye disease accounts for nearly 25% of ophthalmology consultations, making it a commonly encountered condition. When conventional treatments fail autologous serum in the form of eye drops, have been proposed as a therapeutic option. With the aim of standardizing the preparation of autologous serum eye drops in France, the main objective is to describe the absolute and relative differences (before and after filtration) in the concentrations of active molecules in the autologous serum of patients suffering from severe dry eye disease.

Conditions

  • Dry Eye Syndrome (DES)

Interventions

BIOLOGICAL

Serum dosage of TGF-β, IGF-1, EGF, Fibronectin and Vitamin A

Dosage of active molecules of autologous serum: TGF β, IGF 1, EGF, fibronectin and vitamin A

Sponsors & Collaborators

  • University Hospital, Limoges

    lead OTHER

Principal Investigators

  • Maxime Rocher, Dr · University Hospital, Limoges

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-13
Primary Completion
2026-05-18
Completion
2026-05-18

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07407101 on ClinicalTrials.gov